AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life.

We believe that OMIC technologies represent an important first step towards gaining biological insights into:

  • How drugs work, giving them added value, reducing attrition rates and advancing  through the clinic.
  • Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and monitor drug response.


06/16/2021 | Aromics and Bermes project advances at EBAN CONGRESS 2021
Dr  Plasencia CEO, will be presenting the latest advances of the company... More

05/29/2021 | Asbestos on debat: Meeting with Macosa-Alstom Retirees affected by Asbestos
On 29 May at 11 a.m., will take place in Pla├ža Ramon Calsina in Poblenou, Barcelona,... More


05/13/2021 | AROMICS among the top 40 companies to invest in Europe
InvestHorizon is a programme financed by the European Commission, in association... More

01/12/2021 | Aromics selected at the program of EIT Health investor network
As part of the strategy to attract investment for the clinical development of... More